Karolinska Development's portfolio company Modus Therapeutics receives approval for second part of phase 2 study in chronic kidney disease with anemia

STOCKHOLM, SWEDEN November 4, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company, Modus Therapeutics, has received regulatory approval to initiate the ...

Fulcrum Therapeutics to Present New Clinical Data from the PIONEER trial of Pociredir in Sickle Cell Disease at the 67th American Society of Hematology Annual Meeting

Pociredir Phase 1b PIONEER Trial Data in Sickle Cell Disease to be Presented and Published, Including 12 mg and 20 mg Cohorts ―― Live and ...

Disc Medicine Announces Presentation of Initial Data from RALLY-MF Phase 2 Trial in Patients with Myelofibrosis (MF) and Anemia at the 67th American Society of Hematology (ASH ...

Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious ...
Yahoo Finance

Iron Deficiency Anemia Therapy Market to Reach USD 10.94 Billion by 2034, Driven by Rising Cases and Expanding R&D Activities

Ottawa, Nov. 03, 2025 (GLOBE NEWSWIRE) -- The global iron deficiency anemia therapy market size was valued at USD 5.24 ...
Ottawa Citizen

How science in space is helping rehab patients on Earth

The research led by Ottawa's Dr. Guy Trudel is one of four new Canadian studies to be conducted aboard the International ...